These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37130851)

  • 1. Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery.
    Hsueh HT; Chou RT; Rai U; Liyanage W; Kim YC; Appell MB; Pejavar J; Leo KT; Davison C; Kolodziejski P; Mozzer A; Kwon H; Sista M; Anders NM; Hemingway A; Rompicharla SVK; Edwards M; Pitha I; Hanes J; Cummings MP; Ensign LM
    Nat Commun; 2023 May; 14(1):2509. PubMed ID: 37130851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.
    Chiang B; Kim YC; Doty AC; Grossniklaus HE; Schwendeman SP; Prausnitz MR
    J Control Release; 2016 Apr; 228():48-57. PubMed ID: 26930266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.
    Fedorchak MV; Conner IP; Medina CA; Wingard JB; Schuman JS; Little SR
    Exp Eye Res; 2014 Aug; 125():210-6. PubMed ID: 24983144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
    Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
    Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation.
    Bigdeli A; Makhmalzadeh BS; Feghhi M; SoleimaniBiatiani E
    Drug Deliv Transl Res; 2023 Apr; 13(4):1035-1047. PubMed ID: 36477776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device.
    Samy KE; Cao Y; Kim J; Konichi da Silva NR; Phone A; Bloomer MM; Bhisitkul RB; Desai TA
    J Ocul Pharmacol Ther; 2019 Mar; 35(2):124-131. PubMed ID: 30615539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metal-organic frameworks, NH
    Kim SN; Park CG; Huh BK; Lee SH; Min CH; Lee YY; Kim YK; Park KH; Choy YB
    Acta Biomater; 2018 Oct; 79():344-353. PubMed ID: 30134206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.
    Emad Eldeeb A; Salah S; Ghorab M
    Drug Deliv; 2019 Dec; 26(1):509-521. PubMed ID: 31090464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.
    Kim YC; Hsueh HT; Shin MD; Berlinicke CA; Han H; Anders NM; Hemingway A; Leo KT; Chou RT; Kwon H; Appell MB; Rai U; Kolodziejski P; Eberhart C; Pitha I; Zack DJ; Hanes J; Ensign LM
    Drug Deliv Transl Res; 2022 Apr; 12(4):826-837. PubMed ID: 33900546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma.
    Sharma PK; Chauhan MK
    Curr Eye Res; 2021 Nov; 46(11):1703-1716. PubMed ID: 33844617
    [No Abstract]   [Full Text] [Related]  

  • 11. Brimonidine-montmorillonite hybrid formulation for topical drug delivery to the eye.
    Park CG; Choi G; Kim MH; Kim SN; Lee H; Lee NK; Choy YB; Choy JH
    J Mater Chem B; 2020 Sep; 8(35):7914-7920. PubMed ID: 32726382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.
    Zhao Y; Huang C; Zhang Z; Hong J; Xu J; Sun X; Sun J
    Drug Deliv; 2022 Dec; 29(1):613-623. PubMed ID: 35174743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
    Aburahma MH; Mahmoud AA
    AAPS PharmSciTech; 2011 Dec; 12(4):1335-47. PubMed ID: 21979886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study.
    Gautam N; Kesavan K
    Curr Eye Res; 2021 Dec; 46(12):1844-1852. PubMed ID: 34176380
    [No Abstract]   [Full Text] [Related]  

  • 15. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.
    Kompella UB; Hartman RR; Patil MA
    Prog Retin Eye Res; 2021 May; 82():100901. PubMed ID: 32891866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
    Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
    Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional properties of organic-inorganic hybrid nanocomposites based on chitosan derivatives and layered double hydroxides for ocular drug delivery.
    Xu T; Zhang J; Chi H; Cao F
    Acta Biomater; 2016 May; 36():152-63. PubMed ID: 26940970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
    Walters TR
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
    Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
    PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
    Lusthaus JA; Goldberg I
    Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.